Company intelligence / Profile preview
PIKSci
Toronto, Ontario, Canadapiksci.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
PIKSci is a private biotechnology company developing novel therapeutics centered on PIKfyve inhibition, with an initial focus on cancer and particular emphasis on B-cell malignancies. Publicly available materials indicate the company is advancing small-molecule programs that target lysosomal biology and autophagy, and it has described broader interest in autoimmune disease and viral infection. The company has presented preclinical data on a lead candidate, PIK-001, for multiple myeloma and related hematologic cancers, and it also holds patent-protected triazolo-pyrimidine chemical matter associated with PIKfyve inhibition. PIKSci appears to be based in Toronto, Canada and remains privately held.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on PIKSci.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIKSci.